(Q84220239)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632031%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

title

Induction of DNA strand breaks is critical to predict the cytotoxicity of gemtuzumab ozogamicin against leukemic cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632031%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

Takahiro Yamauchi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632031%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Yasufumi Matsuda

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632031%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Toshiki Tasaki

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632031%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Eiju Negoro

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632031%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Satoshi Ikegaya

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632031%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Kazutaka Takagi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632031%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Akira Yoshida

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632031%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Yoshimasa Urasaki

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632031%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Takanori Ueda

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632031%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

publication date

11 July 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632031%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632031%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

103

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632031%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632031%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

1722-1729

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632031%20AND%20SRC:MED&resulttype=core&format=json

CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy

2 February 2020

cites work

1 reference

12 December 2020

Cleavage of cellular DNA by calicheamicin gamma1.

1 reference

12 December 2020

Growth arrest and DNA damage-45 alpha (GADD45alpha).

1 reference

12 December 2020

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

1 reference

12 December 2020

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia

1 reference

12 December 2020

Loss of CD20 antigen expression after rituximab therapy of CD20 positive B cell lymphoma (diffuse large B cell extranodal marginal zone lymphoma combination): a case report and review of the literature

1 reference

12 December 2020

ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P

1 reference

12 December 2020

Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells.

1 reference

12 December 2020

A simple technique for quantitation of low levels of DNA damage in individual cells

1 reference

12 December 2020

Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed

1 reference

12 December 2020

Simultaneous treatment with 1-beta-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells

1 reference

12 December 2020

Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin

1 reference

12 December 2020

Exclusive production of bistranded DNA damage by calicheamicin.

1 reference

12 December 2020

Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3.

1 reference

12 December 2020

Differences in CD33 intensity between various myeloid neoplasms

1 reference

12 December 2020

Deficient activation of Bak and Bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML.

1 reference

12 December 2020

New trends in the standard of care for initial therapy of acute myeloid leukemia

1 reference

12 December 2020

Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model?

1 reference

12 December 2020

Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity

1 reference

12 December 2020

Characterization of cytarabine-resistant leukemic cell lines established from five different blood cell lineages using gene expression and proteomic analyses

1 reference

12 December 2020

Age and acute myeloid leukemia

1 reference

12 December 2020

Genomic instability, centrosome amplification, cell cycle checkpoints and Gadd45a

1 reference

12 December 2020

Gemtuzumab ozogamicin: is there room for salvage?

1 reference

12 December 2020

Effect of gemtuzumab ozogamicin on acute myeloid leukemia blast cells in vitro, as a single agent and combined with other cytotoxic cells

1 reference

12 December 2020

Mechanisms of double-strand break repair in somatic mammalian cells

1 reference

12 December 2020

[Monoclonal antibody therapies for acute leukemia]

1 reference

12 December 2020

Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin

1 reference

12 December 2020

Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining.

1 reference

12 December 2020

Fludarabine-mediated circumvention of cytarabine resistance is associated with fludarabine triphosphate accumulation in cytarabine-resistant leukemic cells

1 reference

12 December 2020

Multidrug transporter proteins and cellular factors involved in free and mAb linked calicheamicin-gamma1 (gentuzumab ozogamicin, GO) resistance and in the selection of GO resistant variants of the HL60 AML cell line

1 reference

12 December 2020

Calicheamicin-DNA complexes: warhead alignment and saccharide recognition of the minor groove

1 reference

12 December 2020

Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the "comet" assay

1 reference

12 December 2020

Targeting abnormal DNA double strand break repair in cancer

1 reference

12 December 2020

Gemtuzumab ozogamicin: one size does not fit all--the case for personalized therapy

1 reference

12 December 2020

Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair.

1 reference

12 December 2020

Establishment of a daunorubicin-resistant cell line which shows multi-drug resistance by multifactorial mechanisms.

1 reference

12 December 2020

Drug therapy for acute myeloid leukemia

1 reference

12 December 2020

New approaches in acute myeloid leukemia

1 reference

12 December 2020

Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia.

1 reference

12 December 2020

UCN-01 (7-hydroxystaurosporine) inhibits DNA repair and increases cytotoxicity in normal lymphocytes and chronic lymphocytic leukemia lymphocytes.

1 reference

12 December 2020

Mechanism and regulation of human non-homologous DNA end-joining

1 reference

12 December 2020

10.1111/J.1349-7006.2012.02343.X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22632031%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference